AG˹ٷ

STOCK TITAN

[8-K] ABBVIE INC. Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Harte Hanks (HHS) has filed a Form 4 revealing that General Counsel Robert T. Wyman received 25,000 restricted stock units (RSUs) on 2 June 2025 at a reference price of $4.55 per share. The RSUs vest in three equal annual tranches on each anniversary of the grant date, encouraging long-term retention and alignment with shareholder interests.

After the award, Wyman reports 27,217 directly held common shares and 33,334 unvested RSUs�25,000 from the new 2025 grant plus 8,334 remaining from a 12,500-share grant made on 4 Mar 2024. The RSUs are held indirectly by the company until they vest, and no derivative securities, option exercises or open-market transactions were disclosed.

The filing represents routine executive equity compensation rather than an outright purchase. Immediate cash outlay is zero, and the incremental dilution from 25,000 shares is expected to be negligible relative to the company’s total share count. While the grant reinforces incentive alignment, it is unlikely to have a material impact on Harte Hanks� near-term valuation or trading dynamics.

Harte Hanks (HHS) ha presentato un Modulo 4 che rivela che il Consulente Legale Robert T. Wyman ha ricevuto 25.000 unità azionarie vincolate (RSU) il 2 giugno 2025 a un prezzo di riferimento di 4,55 $ per azione. Le RSU maturano in tre tranche annuali uguali in ogni anniversario della data di assegnazione, favorendo la fidelizzazione a lungo termine e l'allineamento con gli interessi degli azionisti.

Dopo l'assegnazione, Wyman dichiara di detenere 27.217 azioni ordinarie direttamente possedute e 33.334 RSU non ancora maturate�25.000 dalla nuova assegnazione del 2025 più 8.334 residue da un'assegnazione di 12.500 azioni effettuata il 4 marzo 2024. Le RSU sono detenute indirettamente dalla società fino alla maturazione e non sono state segnalate operazioni con strumenti derivati, esercizi di opzioni o transazioni sul mercato aperto.

La comunicazione rappresenta una normale compensazione azionaria per dirigenti piuttosto che un acquisto diretto. L'esborso immediato in contanti è zero e la diluizione incrementale di 25.000 azioni è prevista come trascurabile rispetto al numero totale di azioni della società. Sebbene l'assegnazione rafforzi l'allineamento degli incentivi, è improbabile che abbia un impatto significativo sulla valutazione a breve termine o sulle dinamiche di trading di Harte Hanks.

Harte Hanks (HHS) ha presentado un Formulario 4 que revela que el Consejero General Robert T. Wyman 𳦾ó 25,000 unidades de acciones restringidas (RSU) el 2 de junio de 2025 a un precio de referencia de $4.55 por acción. Las RSU se consolidan en tres tramos anuales iguales en cada aniversario de la fecha de concesión, promoviendo la retención a largo plazo y la alineación con los intereses de los accionistas.

Tras la adjudicación, Wyman informa tener 27,217 acciones ordinarias en propiedad directa y 33,334 RSU no consolidadas�25,000 del nuevo otorgamiento de 2025 más 8,334 restantes de una concesión de 12,500 acciones realizada el 4 de marzo de 2024. Las RSU se mantienen indirectamente por la empresa hasta que se consolidan, y no se divulgaron valores derivados, ejercicios de opciones ni transacciones en mercado abierto.

La presentación representa una compensación accionaria ejecutiva rutinaria en lugar de una compra directa. No hay desembolso de efectivo inmediato y la dilución incremental de 25,000 acciones se espera que sea insignificante en relación con el total de acciones de la compañía. Aunque la concesión refuerza la alineación de incentivos, es poco probable que tenga un impacto material en la valoración o dinámica de negociación a corto plazo de Harte Hanks.

Harte Hanks(HHS)� Robert T. Wyman 법률 고문� 2025� 6� 2�� 주당 $4.55� 기준 가격으� 25,000개의 제한 주식 단위(RSU)� 받았음을 밝히� Form 4� 제출했습니다. RSU� 부여일 매년 기념일에 � 번에 걸쳐 동일� 비율� 권리가 확정되어 장기적인 직원 유지왶 주주 이익과의 정렬� 장려합니�.

수여 � Wyman은 직접 보유 중인 보통� 27,217�미확� RSU 33,334��2025� 신규 부여분 25,000주왶� 2024� 3� 4� 부여된 12,500� � 남은 8,334주를 보고했습니다. RSU� 권리 확정 전까지 회사가 간접적으� 보유하며 파생 증권, 옵션 행사 또는 공개 시장 거래� 보고되지 않았습니�.

이번 제출은 직접 매수가 아닌 일상적인 경영� 주식 보상� 해당합니�. 즉각적인 현금 지출은 없으� 25,000주에 따른 희석 효과� 회사 � 주식 수에 비해 미미� 것으� 예상됩니�. 이번 부여는 인센티브 정렬� 강화하지� Harte Hanks� 단기 가� 평가� 거래 동향� 중대� 영향� 미칠 가능성은 낮습니다.

Harte Hanks (HHS) a déposé un formulaire 4 révélant que le conseiller juridique Robert T. Wyman a reçu 25 000 unités d'actions restreintes (RSU) le 2 juin 2025 à un prix de référence de 4,55 $ par action. Les RSU se libèrent en trois tranches annuelles égales à chaque anniversaire de la date d'attribution, favorisant la rétention à long terme et l'alignement avec les intérêts des actionnaires.

Après cette attribution, Wyman déclare détenir 27 217 actions ordinaires en direct ainsi que 33 334 RSU non acquises�25 000 provenant de la nouvelle attribution de 2025 plus 8 334 restantes d'une attribution de 12 500 actions effectuée le 4 mars 2024. Les RSU sont détenues indirectement par la société jusqu'à leur acquisition, et aucune opération sur titres dérivés, exercice d'options ou transaction sur le marché ouvert n'a été divulguée.

Ce dépôt représente une rémunération en actions habituelle pour les dirigeants plutôt qu'un achat direct. Aucun décaissement immédiat en espèces n'est requis, et la dilution supplémentaire de 25 000 actions devrait être négligeable par rapport au nombre total d'actions de la société. Bien que cette attribution renforce l'alignement des incitations, elle est peu susceptible d'avoir un impact significatif sur la valorisation ou la dynamique de négociation à court terme de Harte Hanks.

Harte Hanks (HHS) hat ein Formular 4 eingereicht, das offenlegt, dass der General Counsel Robert T. Wyman am 2. Juni 2025 25.000 Restricted Stock Units (RSUs) zu einem Referenzpreis von 4,55 $ pro Aktie erhalten hat. Die RSUs werden in drei gleichen jährlichen Tranchen jeweils am Jahrestag des Gewährungsdatums fällig, was eine langfristige Bindung und die Ausrichtung an den Interessen der Aktionäre fördert.

Nach der Zuteilung meldet Wyman 27.217 direkt gehaltene Stammaktien sowie 33.334 nicht fällige RSUs�25.000 aus der neuen Zuteilung 2025 plus 8.334 aus einer 12.500-Aktien-Zuteilung vom 4. März 2024. Die RSUs werden bis zur Fälligkeit indirekt vom Unternehmen gehalten, und es wurden keine derivative Wertpapiere, Optionsausübungen oder Transaktionen am offenen Markt offengelegt.

Die Meldung stellt eine routinemäßige Aktienvergütung für Führungskräfte dar und keinen direkten Kauf. Es fallen keine sofortigen Barausgaben an, und die zusätzliche Verwässerung durch 25.000 Aktien wird im Verhältnis zur Gesamtzahl der Aktien des Unternehmens voraussichtlich vernachlässigbar sein. Obwohl die Zuteilung die Anreizausrichtung stärkt, wird sie wahrscheinlich keinen wesentlichen Einfluss auf die kurzfristige Bewertung oder das Handelsgeschehen von Harte Hanks haben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 25,000 RSU grant to General Counsel; routine equity award; neutral impact.

The 2 Jun 2025 Form 4 shows Harte Hanks� General Counsel receiving 25,000 RSUs at $4.55, vesting over three years. Post-grant ownership totals 27,217 direct shares plus 33,334 unvested RSUs. No sales, options or derivatives were reported. Such grants are standard compensation tools, producing minimal dilution and no immediate cash effect. Market impact is therefore neutral and largely informational.

Harte Hanks (HHS) ha presentato un Modulo 4 che rivela che il Consulente Legale Robert T. Wyman ha ricevuto 25.000 unità azionarie vincolate (RSU) il 2 giugno 2025 a un prezzo di riferimento di 4,55 $ per azione. Le RSU maturano in tre tranche annuali uguali in ogni anniversario della data di assegnazione, favorendo la fidelizzazione a lungo termine e l'allineamento con gli interessi degli azionisti.

Dopo l'assegnazione, Wyman dichiara di detenere 27.217 azioni ordinarie direttamente possedute e 33.334 RSU non ancora maturate�25.000 dalla nuova assegnazione del 2025 più 8.334 residue da un'assegnazione di 12.500 azioni effettuata il 4 marzo 2024. Le RSU sono detenute indirettamente dalla società fino alla maturazione e non sono state segnalate operazioni con strumenti derivati, esercizi di opzioni o transazioni sul mercato aperto.

La comunicazione rappresenta una normale compensazione azionaria per dirigenti piuttosto che un acquisto diretto. L'esborso immediato in contanti è zero e la diluizione incrementale di 25.000 azioni è prevista come trascurabile rispetto al numero totale di azioni della società. Sebbene l'assegnazione rafforzi l'allineamento degli incentivi, è improbabile che abbia un impatto significativo sulla valutazione a breve termine o sulle dinamiche di trading di Harte Hanks.

Harte Hanks (HHS) ha presentado un Formulario 4 que revela que el Consejero General Robert T. Wyman 𳦾ó 25,000 unidades de acciones restringidas (RSU) el 2 de junio de 2025 a un precio de referencia de $4.55 por acción. Las RSU se consolidan en tres tramos anuales iguales en cada aniversario de la fecha de concesión, promoviendo la retención a largo plazo y la alineación con los intereses de los accionistas.

Tras la adjudicación, Wyman informa tener 27,217 acciones ordinarias en propiedad directa y 33,334 RSU no consolidadas�25,000 del nuevo otorgamiento de 2025 más 8,334 restantes de una concesión de 12,500 acciones realizada el 4 de marzo de 2024. Las RSU se mantienen indirectamente por la empresa hasta que se consolidan, y no se divulgaron valores derivados, ejercicios de opciones ni transacciones en mercado abierto.

La presentación representa una compensación accionaria ejecutiva rutinaria en lugar de una compra directa. No hay desembolso de efectivo inmediato y la dilución incremental de 25,000 acciones se espera que sea insignificante en relación con el total de acciones de la compañía. Aunque la concesión refuerza la alineación de incentivos, es poco probable que tenga un impacto material en la valoración o dinámica de negociación a corto plazo de Harte Hanks.

Harte Hanks(HHS)� Robert T. Wyman 법률 고문� 2025� 6� 2�� 주당 $4.55� 기준 가격으� 25,000개의 제한 주식 단위(RSU)� 받았음을 밝히� Form 4� 제출했습니다. RSU� 부여일 매년 기념일에 � 번에 걸쳐 동일� 비율� 권리가 확정되어 장기적인 직원 유지왶 주주 이익과의 정렬� 장려합니�.

수여 � Wyman은 직접 보유 중인 보통� 27,217�미확� RSU 33,334��2025� 신규 부여분 25,000주왶� 2024� 3� 4� 부여된 12,500� � 남은 8,334주를 보고했습니다. RSU� 권리 확정 전까지 회사가 간접적으� 보유하며 파생 증권, 옵션 행사 또는 공개 시장 거래� 보고되지 않았습니�.

이번 제출은 직접 매수가 아닌 일상적인 경영� 주식 보상� 해당합니�. 즉각적인 현금 지출은 없으� 25,000주에 따른 희석 효과� 회사 � 주식 수에 비해 미미� 것으� 예상됩니�. 이번 부여는 인센티브 정렬� 강화하지� Harte Hanks� 단기 가� 평가� 거래 동향� 중대� 영향� 미칠 가능성은 낮습니다.

Harte Hanks (HHS) a déposé un formulaire 4 révélant que le conseiller juridique Robert T. Wyman a reçu 25 000 unités d'actions restreintes (RSU) le 2 juin 2025 à un prix de référence de 4,55 $ par action. Les RSU se libèrent en trois tranches annuelles égales à chaque anniversaire de la date d'attribution, favorisant la rétention à long terme et l'alignement avec les intérêts des actionnaires.

Après cette attribution, Wyman déclare détenir 27 217 actions ordinaires en direct ainsi que 33 334 RSU non acquises�25 000 provenant de la nouvelle attribution de 2025 plus 8 334 restantes d'une attribution de 12 500 actions effectuée le 4 mars 2024. Les RSU sont détenues indirectement par la société jusqu'à leur acquisition, et aucune opération sur titres dérivés, exercice d'options ou transaction sur le marché ouvert n'a été divulguée.

Ce dépôt représente une rémunération en actions habituelle pour les dirigeants plutôt qu'un achat direct. Aucun décaissement immédiat en espèces n'est requis, et la dilution supplémentaire de 25 000 actions devrait être négligeable par rapport au nombre total d'actions de la société. Bien que cette attribution renforce l'alignement des incitations, elle est peu susceptible d'avoir un impact significatif sur la valorisation ou la dynamique de négociation à court terme de Harte Hanks.

Harte Hanks (HHS) hat ein Formular 4 eingereicht, das offenlegt, dass der General Counsel Robert T. Wyman am 2. Juni 2025 25.000 Restricted Stock Units (RSUs) zu einem Referenzpreis von 4,55 $ pro Aktie erhalten hat. Die RSUs werden in drei gleichen jährlichen Tranchen jeweils am Jahrestag des Gewährungsdatums fällig, was eine langfristige Bindung und die Ausrichtung an den Interessen der Aktionäre fördert.

Nach der Zuteilung meldet Wyman 27.217 direkt gehaltene Stammaktien sowie 33.334 nicht fällige RSUs�25.000 aus der neuen Zuteilung 2025 plus 8.334 aus einer 12.500-Aktien-Zuteilung vom 4. März 2024. Die RSUs werden bis zur Fälligkeit indirekt vom Unternehmen gehalten, und es wurden keine derivative Wertpapiere, Optionsausübungen oder Transaktionen am offenen Markt offengelegt.

Die Meldung stellt eine routinemäßige Aktienvergütung für Führungskräfte dar und keinen direkten Kauf. Es fallen keine sofortigen Barausgaben an, und die zusätzliche Verwässerung durch 25.000 Aktien wird im Verhältnis zur Gesamtzahl der Aktien des Unternehmens voraussichtlich vernachlässigbar sein. Obwohl die Zuteilung die Anreizausrichtung stärkt, wird sie wahrscheinlich keinen wesentlichen Einfluss auf die kurzfristige Bewertung oder das Handelsgeschehen von Harte Hanks haben.

0001551152false00015511522025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XNYS2025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XCHI2025-07-032025-07-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-07-032025-07-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 3, 2025
 
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)
 _____________________________________________________
1 North Waukegan Road
North ChicagoIllinois 60064-6400
(Address of principal executive offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (847) 932-7900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 Par Value ABBV New York Stock Exchange
NYSE Texas
0.750% Senior Notes due 2027ABBV27New York Stock Exchange
2.125% Senior Notes due 2028ABBV28New York Stock Exchange
2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange
2.125% Senior Notes due 2029ABBV29New York Stock Exchange
1.250% Senior Notes due 2031ABBV31New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    



Item 2.02  Results of Operations and Financial Condition
 
Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April 25, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $11.67 - $11.87. AbbVie’s second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $2.84 - $2.88.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Forward-Looking Statements

Some statements in this Current Report on Form 8-K are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits
Exhibit No. Exhibit
99.1
 
Guidance including the impact of acquired IPR&D and milestones expense.
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  ABBVIE INC.
   
Date:July 3, 2025By:/s/ Scott T. Reents
  Scott T. Reents
  Executive Vice President,
  Chief Financial Officer

 


FAQ

What did Harte Hanks (HHS) report in the latest Form 4?

The company granted 25,000 RSUs to General Counsel Robert Wyman on 2 June 2025, with no shares sold or options exercised.

How many restricted stock units were awarded to Robert Wyman?

He received 25,000 RSUs priced at $4.55 per share.

When will the 25,000 RSUs vest?

They vest in three equal annual tranches on each anniversary of the 2 June 2025 grant date.

What is Robert Wyman’s total reported ownership after the grant?

He holds 27,217 direct shares and 33,334 unvested RSUs (25,000 from 2025 and 8,334 from a 2024 grant).

Were any shares sold or derivative securities reported?

No. The Form 4 shows only the RSU grant; there were no sales, option exercises, or derivative positions disclosed.
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Latest News

ABBV Latest SEC Filings

ABBV Stock Data

334.34B
1.76B
0.12%
74.08%
1.05%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
NORTH CHICAGO